Quality-of-life assessment in French patients with metastatic melanoma in real life

Marguerite Kandel, Stéphane Dalle, Aurélie Bardet, Clara Allayous, Laurent Mortier, Caroline Dutriaux, Bernard Guillot, Marie Thérèse Leccia, Sophie Dalac, Delphine Legoupil, Philippe Saiag, Henri Montaudie, Jean Philippe Arnault, Florence Brunet-Possenti, Jean Jacques Grob, Julie DeQuatrebarbes, Marie Beylot-Barry, Thierry Lesimple, François Aubin, Eve MaubecFlorence Granel-Brocard, Pierre Emmanuel Stoebner, Alain Dupuy, Brigitte Dreno, Stefan Michiels, Céleste Lebbe, Isabelle Borget

    Research output: Contribution to journalArticlepeer-review

    13 Citations (Scopus)

    Abstract

    Background: Significant progress was recently observed in the treatment of metastatic melanoma (MM). With >50% of patients now reaching a second line of treatment and a significant improvement in the survival rate, an assessment of quality of life (QoL) during the whole course of the disease becomes necessary. The objective of this study was to describe the QoL of patients with MM in France, from their diagnosis of advanced disease to their death, in real life. Methods: QoL data were collected through MelBase, a prospective, French, multicentric cohort dedicated to the follow-up of adults with MM. QoL was assessed using the EuroQoL-5D questionnaire and the Functional Assessment of Cancer Treatment (FACT)-Melanoma questionnaire at the time of study inclusion, every 3 months, and at the time of each treatment change until death. To assess longitudinal changes from baseline to death, mixed-effect models for repeated-measures analyses were used to control for baseline covariates. Results: QoL was assessed in 1435 patients who were included in the study between 2013 and 2018. The median follow-up was 9.4 months, and 47% of patients died during follow-up. During first-line treatment, the model-based, mean utility score was 0.830 (95% CI, 0.818-0.843), the mean FACT-General score was 77.22 (95% CI, 76.23-78.22), and the mean FACT-Melanoma score was 129.46 (95% CI, 128.02-130.90). At the time of a change in treatment line, there was a decrease of −0.027 (95% CI, −0.03, −0.02) in the utility score, −1.82 (95% CI, −1.88, −1.76) in the FACT-General score, and −2.98 (95% CI, −3.05, −2.91) in the FACT-Melanoma score compared with first-line treatment. Conclusions: In the MelBase cohort, the QoL among patients with MM seems to be fairly stable over the whole disease course, although a small but significant decrease at time therapy is changed is observed.

    Original languageEnglish
    Pages (from-to)611-618
    Number of pages8
    JournalCancer
    Volume126
    Issue number3
    DOIs
    Publication statusPublished - 1 Feb 2020

    Keywords

    • clinical practice
    • immunotherapy
    • metastatic melanoma
    • quality of life
    • real-life
    • targeted therapy

    Cite this